R392
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 85
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.560
- MYC_TARGETS_V1+0.510
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V2+0.450
- MTORC1_SIGNALING+0.340
- PROTEIN_SECRETION+0.340
- UNFOLDED_PROTEIN_RESPONSE+0.340
- MITOTIC_SPINDLE+0.250
- DNA_REPAIR+0.220
- INTERFERON_ALPHA_RESPONSE+0.210
Top 10 suppressed
- MYOGENESIS-0.310
- PANCREAS_BETA_CELLS-0.300
- KRAS_SIGNALING_UP-0.270
- TGF_BETA_SIGNALING-0.250
- CHOLESTEROL_HOMEOSTASIS-0.210
- XENOBIOTIC_METABOLISM-0.210
- BILE_ACID_METABOLISM-0.190
- ESTROGEN_RESPONSE_EARLY-0.190
- ALLOGRAFT_REJECTION-0.180
- APICAL_JUNCTION-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7cec44f2-b56b-49fc-b2cc-d0691afde776 | — | — | 0.857 |
| 2 | fac69f81-0d8c-40a0-8263-b54d5f06d7b3 | — | — | 0.825 |
| 3 | SRR12475103 | — | — | 0.817 |
| 4 | SJEPD030168_D1.RNA-Seq | EPN | EPN Tumor | 0.814 |
| 5 | TCGA-91-6836-01A-21R-1858-07 | — | cohortA1 | 0.812 |
| 6 | MDT-AP-3247 | Med | Medulloblastoma | 0.809 |
| 7 | BS_DFGS950G | high-grade glioma | — | 0.806 |
| 8 | MNG979 | — | — | 0.804 |
| 9 | TCGA-AR-A24H-01A-11R-A169-07 | — | B | 0.798 |
| 10 | TCGA-B6-A1KN-01A-11R-A13Q-07 | — | C | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.080 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.050 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.030 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.030 | Inavolisib | — uncovered |